Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

The Pro Medicus (PME) Share Price Is Getting Taken To The Cleaners

Today, the Pro Medicus Limited (ASX: PME) share price got taken to the cleaners. It fell 8% today.

PME Share Price

 

chart shows pro medicus share pricing rising from $10 to over $30 in one year
Source: Google Finance

About Pro Medicus

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria; Berlin, Germany; and in the United States. Its two primary lines of business are Visage imaging software, and Visage RIS — an all-in-one software service for clinics to manage their business. 

In the following video taken last year, I explained the Pro Medicus business in detail and why we bought it for our Rask Invest investing subscription service (we recommended it below $10 per share).

https://youtu.be/0SWl9xBsRNw

Time To Sell?

There was no company-specific news released by Pro Medicus today. It seems to have been caught up in the broader market sell-off, much like Afterpay Touch Group Ltd (ASX: APT) and Appen Limited (ASX: APX).

While no-one likes to see their shares fall, we issued a partial sell-down of our Pro Medicus position a few months ago due to valuation.

Indeed, despite the huge addressable market for its Visage 7 and Vendor Neutral Archive (VNA) platform, particularly in the USA, we couldn’t reasonably justify a price over $11 per share for Pro Medicus so we decided to sell some of our position.

We’re happy to hold part of our original position because we think Pro Medicus is an exceptionally well-run business with aligned management and a great product in a large market. But to be clear: we’re not buyers of the shares today.

Zooming out a little bit, while you may think the opportunity for big long-term returns has passed you by, we here at Rask Invest believe hard-working stock market investors will have plenty of other opportunities to look forward to over the next 10 years. You just have to remain patient and look in the right places!

[ls_content_block id=”14947″ para=”paragraphs”]

Disclosure: At the time of writing, Owen owns shares of Pro Medicus. 

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content